On September 10, 2024, Evopoint Biosciences Co., Ltd. was informed by CDE of NMPA that the EZH2 inhibitor XNW5004 has officially been designated as ...
On June 14, 2024, XNW27011, a new-generation Antibody-Coupled Drug (ADC) developed by Evopoint, has been granted Fast Track Designation (FTD) status...
Evopoint independently developed a new small molecule selective URAT1 inhibitor, XNW3009.
Follow us
